Results 261 to 270 of about 274,980 (287)

Pregabalin (Pfizer).

Current opinion in investigational drugs (London, England : 2000), 2001
Pfizer is developing pregabalin, a follow-up compound to its GABA agonist gabapentin, for the potential treatment of several central nervous system (CNS) disorders including epilepsy, neuropathic pain, anxiety and social phobia [286425]. By December 2000, Pfizer anticipated filing an NDA for pregabalin for seven major indications (beginning with ...
openaire   +1 more source

Canertinib pfizer.

IDrugs : the investigational drugs journal, 2004
Canertinib, a water-soluble, orally available analog of PD-169414 (Pfizer Inc), is an EGFR tyrosine kinase inhibitor under development by Pfizer Inc as a potential treatment for cancer.
openaire   +1 more source

Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Journal of Medical Economics, 2022
Manuela Di Fusco, Mary M Moran, Alejandro Cane   +2 more
exaly  

Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine

Human Vaccines and Immunotherapeutics, 2021
Roberto Scendoni
exaly  

“Pfizer”

IIC - International Review of Intellectual Property and Competition Law, 2014
openaire   +1 more source

Vulvar Aphthous Ulcer Following Pfizer-BioNTech COVID-19 Vaccine – A Case Report

Journal of Pediatric and Adolescent Gynecology, 2022
exaly  

Minimal change disease soon after Pfizer-BioNTech COVID-19 vaccination

CKJ: Clinical Kidney Journal, 2021
Hiroyuki Terawaki, Fugo Kazunori, Yamazaki Kazuto   +2 more
exaly  

Pfizer

2023
openaire   +1 more source

Pfizer and others invest in Carrick

C&EN Global Enterprise, 2022
Gina Vitale
exaly  

Pfizer

Industrial & Engineering Chemistry, 1959
openaire   +1 more source